As for KIFC3, another kinesin-14 family member, was reported to promote HCC development via the PI3K/Akt/mTOR signaling axis, and the stimulative action of KIFC3 could be suppressed by addition of LY294002 (a highly selective inhibitor targeting PI3K), and combining with KIFC3-depletion and LY294002 treatment displayed a synergistic inhibitory effect, suggesting the potential therapeutic value of KIFC3 in HCC [114] (Fig. 5C). The gene discussed is MTOR; the disease is hepatocellular carcinoma.